NCT02534753

A Pharmacokinetics Study of Intravenous Ascorbic Acid

A Phase 1, Single-Dose Study to Evaluate the Pharmacokinetics of Intravenous Ascorbic Acid in Healthy Male and Female Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: McGuff Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This is a Phase 1, single-dose study to evaluate the pharmacokinetics of intravenous Ascorbic Acid.

Detailed description

The objectives of this study are: 1. To evaluate the single-dose pharmacokinetics of AA administered intravenously (IV). 2. To evaluate the safety and tolerability of AA administered intravenously.

Conditions

• Pharmacokinetics

Interventions

Type	Name	Description
DRUG	Ascor L 500® (Ascorbic Acid Injection, USP)	A sterile, solution containing 500 mg ascorbic acid per mL

Timeline

• Start date: 2015-09-01
• Primary completion: 2015-11-01
• Completion: 2016-01-01
• First posted: 2015-08-28
• Last updated: 2016-03-23

Locations

1 site across 1 country: United States